Latest Artemisinin Stories
Malaria-drug monitoring over the past 30 years has shown that malaria parasites develop resistance to medicine, and the first signs of resistance to the newest drugs have just been observed.
A pair of provocative studies in the July 2012 issue of The American Journal of Tropical Medicine and Hygiene (AJTMH) provides a window into the intense ground war now underway against malaria.
Giving young children medicine once a month during the rainy season to protect them against malaria could prevent tens of thousands of deaths each year in some areas of Africa.
Scientists are reporting development of a new, higher-yield, two-step, less costly process that may ease supply problems and zigzagging prices for the raw material essential for making the mainstay drug for malaria.
Poor quality antimalarial drugs lead to drug resistance and inadequate treatment that pose an urgent threat to vulnerable populations, according to a National Institutes of Health study published May 22 in The Lancet Infectious Diseases journal.
Scientists have expressed concerns that resistance to the primary treatment for malaria is increasing, potentially putting thousands of additional people at risk of losing their lives to the disease.
Evidence that the most deadly species of malaria parasite, Plasmodium falciparum, is becoming resistant to the front line treatment for malaria on the border of Thailand and Myanmar (Burma) is reported in The Lancet today.
Emergence of resistance to the drug artemisinin in western Thailand has created a critical point in global efforts to control and eliminate malaria worldwide.
A chemically altered osteoporosis drug may be useful in fighting malaria, researchers report in a new study. Unlike similar compounds tested against other parasitic protozoa, the drug readily crosses into the red blood cells of malaria-infected mice and kills the malaria parasite.
- A person in a secondary role, specifically the second most important character (after the protagonist).